# US 2022/0008558 A1 · Materials and methods for treatment of hereditary haemochromatosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008558 A1
- Document ID: US20220008558A1
- Status: Published application
- Kind: A1
- Application number: 17/371,386
- Filed: 2021-07-09
- Published: 2022-01-13
- Earliest claimed: 2016-03-16
- Assignees: Crispr Therapeutics AG
- Applicants: Crispr Therapeutics AG
- Inventors: Roman Lvovitch Bogorad; Chad Albert Cowan; Ante Sven Lundberg
- Web page: https://patentgrep.com/patent/US20220008558A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 5/067: {Hepatocytes}
- C12N 9/224: {Class 1 CAS enzyme complex, e.g. multi-enzyme}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.

## Claims

### Claim 1

A method for editing a haemochromatosis (HFE) gene in a human cell by genome editing, the method comprising:
introducing into the human cell one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs) within or near the HFE gene or other DNA sequences that encode regulatory elements of the HFE gene that results in a permanent deletion, insertion, correction, or modulation of expression or function of one or more mutations within or near or affecting the expression or function of the HFE gene and results in restoration of HFE protein activity.

### Claim 2

A method for inserting a haemochromatosis (HFE) gene in a human cell by genome editing, the method comprising:
introducing into the human cell one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs) within or near a safe harbor locus that results in a permanent insertion of the HFE gene, and results in restoration of HFE protein activity.

### Claim at position 3

-22. (canceled)

### Claim 23

An in vivo method for treating a patient with hereditary hemochromatosis (HHC), the method comprising the step of editing a haemochromatosis (HFE) gene in a cell of the patient or other DNA sequences that encode regulatory elements of the HFE gene, or editing within or near a safe harbor locus in a cell of the patient.

### Claim 24 (depends on 23)

The method of claim 23, wherein the editing step comprises:
introducing into the cell one or more deoxyribonucleic acid (DNA) endonucleases to effect one or more single-strand breaks (SSBs) or double-strand breaks (DSBs) within or near the HFE gene or other DNA sequences that encode regulatory elements of the HFE gene that results in a permanent deletion, insertion, correction, or modulation of expression or function of one or more mutations within or near or affecting the expression or function of the HFE gene or within or near a safe harbor locus that results in restoration of HFE protein activity.

### Claim 25 (depends on 23)

The method of claim 23, wherein the one or more DNA endonucleases is a Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas100, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, or Cpf1 endonuclease; a homolog thereof, a recombination of the naturally occurring molecule thereof, codon-optimized thereof, or modified versions thereof, and combinations thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the method comprises introducing into the cell one or more polynucleotides encoding the one or more DNA endonucleases.

### Claim 27 (depends on 25)

The method of claim 25, wherein the method comprises: introducing into the cell one or more ribonucleic acids (RNAs) encoding the one or more DNA endonucleases.

### Claim at position 9

-29. (canceled)

### Claim 30 (depends on 23)

The method of claim 23, wherein the method further comprises: introducing into the cell one or more guide ribonucleic acids (gRNAs).

### Claim 31 (depends on 30)

The method of claim 30, wherein the one or more gRNAs are single-molecule guide RNA (sgRNAs).

### Claim 32 (depends on 31)

The method of claim 31, wherein the one or more sgRNAs is one or more modified sgRNAs.

### Claim 33

(canceled)

### Claim 34 (depends on 23)

The method of claim 23, wherein the method further comprises: introducing into the cell a polynucleotide donor template comprising at least a portion of the wild-type HFE gene, DNA sequences that encode wild-type regulatory elements of the HFE gene or cDNA.

### Claim 35

(canceled)

### Claim 36 (depends on 34)

The method of claim 34, wherein the donor template is either a single or double stranded polynucleotide.

### Claim 37 (depends on 34)

The method of claim 34, wherein the donor template has homologous arms to the 6p21.3 region.

### Claim 38 (depends on 24)

The method of claim 24, wherein the method further comprises:
introducing into the cell one guide ribonucleic acid (gRNA) and a polynucleotide donor template comprising at least a portion of the wild-type HFE gene, and wherein the one or more DNA endonucleases is one or more Cas9 or Cpf1 endonucleases that effect one single-strand break (SSB) or double-strand break (DSB) at a locus within or near the HFE gene or other DNA sequences that encode regulatory elements of the HFE gene, or within or near a safe harbor locus, that facilitates insertion of a new sequence from the polynucleotide donor template into the chromosomal DNA at the locus or safe harbor locus that results in a permanent insertion or correction of a part of the chromosomal DNA of the HFE gene or other DNA sequences that encode regulatory elements of the HFE gene proximal to the locus, or safe harbor locus, and wherein the gRNA comprises a spacer sequence that is complementary to a segment of the locus, or safe harbor locus.

### Claim 39

(canceled)

### Claim 41 (depends on 38)

The method of claim 38, wherein the one or more gRNAs are one or more single-molecule guide RNA (sgRNAs).

### Claim 42 (depends on 41)

The method of claim 41, wherein the one or more gRNAs or one or more sgRNAs is one or more modified gRNAs or one or more modified sgRNAs.

### Claim at position 22

-47. (canceled)

### Claim 48 (depends on 24)

The method of claim 24, wherein the gRNA or sgRNA is directed to one or more of the following pathological variants: C282Y, H63D, S65C, or combinations thereof.

### Claim 49 (depends on 24)

The method of claim 24, wherein the insertion or correction is by homology directed repair (HDR).

### Claim at position 25

-55. (canceled)

### Claim 56 (depends on 24)

The method of claim 24, wherein the Cas9 or Cpf1 mRNA, gRNA, and donor template are either each formulated into separate lipid nanoparticles or all co-formulated into a lipid nanoparticle.

### Claim at position 27

-58. (canceled)

### Claim 59 (depends on 23)

The method of claim 23, wherein the HFE gene is located on Chromosome 6: 26087458-26095569 (Genome Reference Consortium—GRCh38/hg38).

### Claim 60

(canceled)

### Claim 61

One or more guide ribonucleic acids (gRNAs) for editing a haemochromatosis (HFE) gene in a cell from a patient with hereditary hemochromatosis (HHC), the one or more gRNAs comprising a spacer sequence selected from the group consisting of nucleic acid sequences in SEQ ID NOs: 1-64,980 of the Sequence Listing.

### Claim 62 (depends on 61)

The one or more gRNAs of claim 61, wherein the one or more gRNAs are one or more single-molecule guide RNAs (sgRNAs).

### Claim 63 (depends on 62)

The one or more sgRNAs of claim 62, wherein the one or more gRNAs or one or more sgRNAs is one or more modified gRNAs or one or more modified sgRNAs.

### Claim 64 (depends on 62)

The one or more sgRNAs of claim 62, wherein the cell is selected from a group consisting of a liver cell, skin cell, pancreatic cell, heart cell, joint cell, or cell from the testes.

### Claim at position 34

-66. (canceled)
